Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.
The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.
The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.
The uptake among primary care physicians of new migraine drugs has been hindered by 2 significant obstacles, a headache specialist explained to Patient Care Online.
New and highly specific migraine drugs have significantly changed the clinical landscape for patients. We talked with Peter McAllister, MD, about where the research goes next.
Cannabis researchers Drs Carrie Cuttler and Rebecca Craft discuss their findings, their labs at WSU, their new research, and what makes this kind of research a challenge.
Research on pain relief from use of medical cannabis poses myriad challenges. Veteran researchers discuss 2 new studies based on a deep well of user data.
Migraine headaches are a condition commonly seen in primary care. Here is a top-line look at the evidence for efficacy of the wide range of treatments available.
In a phase 2/3 study, nearly half of rimegepant-treated patients demonstrated ≥50% reduction in the number of moderate-to-severe migraine days per month